发明名称 Therapeutic methods
摘要 The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents.
申请公布号 US9119868(B2) 申请公布日期 2015.09.01
申请号 US201214239184 申请日期 2012.08.17
申请人 GlaxoSmithKline LLC 发明人 Walker Jill;Voitenleitner Christian
分类号 A61K31/69;A61K38/21;A61K31/7056;A61K31/343;A61K45/06 主分类号 A61K31/69
代理机构 代理人 Thomas Robert Steve
主权项 1. A method of treatment of Hepatitis C Virus (HCV) in a human in need thereof comprising administering to the human a compound of the structure:or a pharmaceutically acceptable salt thereof, and a second therapeutic agent selected from the group consisting of: an HCV NS2 protease inhibitor, an HCV NS3/4A protease inhibitor, an HCV NS3 helicase inhibitor, an HCV NS4B replication factor inhibitor, an HCV NS5A replication factor inhibitor, an HCV NS5B polymerase inhibitor, an HCV entry inhibitor, an HCV internal ribosome entry site inhibitor, a microsomal triglyceride transfer protein inhibitor, an α-glucosidase inhibitor, a caspase inhibitor, a cyclophilin inhibitor, an immunomodulator, a metabolic pathway inhibitor, an interferon, and a nucleoside analogue.
地址 Wilmington DE US